Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus (Q24201973)

1

0 references

Emmanuel Tsochatzis

2

0 references

Brian R Davidson

6

Brian R Davidson

0 references

Andrew Kenneth Burroughs

5

Andrew K Burroughs

0 references

Clare D Toon

3

Clare D Toon

0 references

Elias Xirouchakis

4

Elias Xirouchakis

0 references

author name string

Brian R Davidson

Cochrane Database of Systematic Reviews

6

0 references

publication date

4 December 2013

0 references

published in

0 references

cites work

A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNα-2a plus ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Daily interferon therapy for hepatitis C virus infection in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Antiviral re-treatment of IFN-ribavirin non-responders for recurrent post-transplantation hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Daily interferon Alpha-2B and ribavirin combination therapy for liver transplant patients with chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Combination therapy with peginterferon alpha-2B and ribavirin in liver transplant recipients with recurrent HCV infection: preliminary results of an open prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Combination therapy of interferon alpha-2B and ribavirin for recurrent hepatitis C after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Combined antiviral therapy for recurrent hepatitis C virus after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Combination therapy for hepatitis C virus reinfection after orthoptic liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Hepatitis C recurrence in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Ribavirin in the treatment of recurrent hepatitis C after liver transplantation: difficult to manage but essential for success.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Natural alpha-IFN in HCV recurrence after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Pegylated interferon (PEG-IFN) alfa-2b and ribavirin for recurrent hepatitis C (genotype 1) after liver transplantation: relationship with steatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Interferon Alfa-2A and ribavirin therapy for hepatitis C recurrence after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Review article: the treatment of hepatitis C virus recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

A model to predict severe HCV-related disease following liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Methods for combining randomized clinical trials: strengths and limitations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

The association between hepatitis C infection and survival after orthotopic liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Assessment of risk of bias in randomized clinical trials in surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Ischemic preconditioning in deceased donor liver transplantation: a prospective randomized clinical trial of safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Industry sponsorship and research outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

A comparison of methods to detect publication bias in meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Intention-to-treat analysis: implications for quantitative and qualitative research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

SPIRIT 2013 statement: defining standard protocol items for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

The influence of viral genotypes and rejection episodes on the recurrence of hepatitis C after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Liver transplantation and hepatitis C virus: systematic review of antiviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Estimating required information size by quantifying diversity in random-effects model meta-analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Antiviral therapy for recurrent liver graft infection with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Antiviral therapy for recurrent liver graft infection with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Effect of ischemic preconditioning in whole liver transplantation from deceased donors. A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

Antiviral treatment of recurrent hepatitis C after liver transplantation: the need for a multifaceted approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

7 January 2021

Treatment of recurrent hepatitis C after liver transplantation with IL-2r Ab

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

7 January 2021

Recurrence of hepatitis C after liver transplantation: follow-up and treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

7 January 2021

Recurrence of HCV infection in liver transplant patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

7 January 2021

Recurrence of hepatitis C in liver transplants from elderly donors aged more than 75 years

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

7 January 2021

Chronic hepatitis C after liver transplantation: a randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

7 January 2021

Extended right split liver graft for primary transplantation in children and adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB4

7 January 2021